Application of predictive models in boosting power of Alzheimer's disease clinical trials: A post hoc analysis of phase 3 solanezumab trials.

Ali EzzatiChristos DavatzikosDavid A WolkCharles B HallChristian HabeckRichard B Lipton

Published in: Alzheimer's & dementia (New York, N. Y.) (2022)

Excluding persons with AD unlikely to decline from the active and placebo arms of clinical trials using predictive models may boost the power of AD trials through selective inclusion of participants expected to decline.

Keyphrases

clinical trial
phase iii
double blind
phase ii
open label
cognitive decline
study protocol
randomized controlled trial
placebo controlled